Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Clinical trial NCT04975555 · COMPLETED

Trial details

NCT number: NCT04975555
Sponsor: University of Alabama at Birmingham
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Cytokine Release Syndrome ICANS Lymphoma, Non-Hodgkin Multiple Myeloma Acute Lymphoblastic Leukemia

Start date: 2021-11-15
Primary completion: 2026-01-20
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.